AMA GYIMAH: Open Payments
NPI 1295597136 · MERIDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,267 in 94 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $1,339 · 2025 $3,267
Food & beverage: $3,156Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $594 |
| Alkermes, Inc. | 15 | $448 |
| E.R. Squibb & Sons, L.L.C. | 14 | $441 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $373 |
| ABBVIE INC. | 12 | $362 |
| Otsuka America Pharmaceutical, Inc. | 7 | $277 |
| Neurocrine BioSciences, Inc. | 6 | $240 |
| Janssen Pharmaceuticals, Inc | 6 | $203 |
| Luye Pharma (USA) Ltd. | 4 | $191 |
| Indivior Inc. | 2 | $57 |
Products named: COBENFY, UZEDY, CAPLYTA, VRAYLAR, INGREZZA, ARISTADA, ERZOFRI EXTENDED-RELEASE, SPRAVATO.
Industry payments across CT — which companies pay providers there.
